Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Guangzhou Healthquest Pharma Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals, assigned across 2 examiners and 2 art units. MOU, LIYUAN is the busiest examiner, with 1 pending action.
The one-to-one distribution across examiners and art units indicates that the portfolio’s current prosecution activity is not concentrated in a single examination channel. Counsel should track each matter separately and avoid assuming that developments in one application will predict treatment in another.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| CHONG, YONG SOO | 1 | 43.8% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18978741 | NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES | MOU, LIYUAN | — |
| 18298800 | Combination Therapies for Treating Cancer | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18978741 | NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES | MOU, LIYUAN | 1628 | §102Other | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18298800 | Combination Therapies for Treating Cancer | CHONG, YONG SOO | 1623 | §103Other | Non-Final OA | — | Pending | Apr 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Healthquest Pharma Co. Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Liyuan Mou has the most, with 1 of Guangzhou Healthquest Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.